| | Control (n = 49) | Intervention (n = 45) | p value |
|---|
| Age, years |
| Mean ± SD | 40.7 ± 10.8 | 37.5 ± 11.7 | 0.171 |
| Median (range) | 42 (18–63) | 36 (21–60) | 0.128 |
| Gender, n (%) |
| Cisgender men | 30 (61.3) | 28 (62.2) | 0.921 |
| Cisgender women | 18 (36.7) | 17 (37.8) | 0.917 |
| Transgender women | 1 (2) | 0 (0) | 0.335 |
| Ethnicity, n (%) |
| White | 4 (8.2) | 4 (8.9) | 0.899 |
| Black | 28 (57.1) | 32 (71.1) | 0.159 |
| Hispanic | 16 (32.7) | 9 (20) | 0.165 |
| Other | 1 (2) | 0 (0) | 0.335 |
| Mode of HIV transmission, n (%) |
| Heterosexual | 30 (61.3) | 29 (64.4) | 0.832 |
| MSM | 15 (30.6) | 12 (26.7) | 0.820 |
| Other | 3 (6.1) | 4 (8.9) | 0.706 |
| Viral load, log10 copies/mL |
| Mean ± SD | 4.7 ± 0.8 | 4.7 ± 1.0 | 1.000 |
| Median (range) | 4.8 (2.4–6.9) | 4.7 (2.2–6.8) | 0.779 |
| CD4 cell count, cells/mL |
| Mean ± SD | 221.8 ± 185.6 | 240.1 ± 230.7 | 0.672 |
| Median (range) | 198 (5–834) | 219 (5–1019) | 0.959 |
| ART regimen, n (%) |
| PI-based | 9 (18.4) | 11 (24.5) | 0.615 |
| NNRTI-based | 21 (42.8) | 24 (53.3) | 0.409 |
| INSTI-based | 19 (38.8) | 10 (22.2) | 0.117 |
- SD standard deviation, MSM men who have sex with men, PI protease inhibitor, INSTI integrase strand transfer inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, ART antiretroviral therapy
